Scheessele William John 4
4 · Humacyte, Inc. · Filed Dec 12, 2023
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Scheessele William John
Chief Commercial Officer
Transactions
- Award
Stock Options (right to buy)
2023-12-08+276,000→ 276,000 totalExercise: $2.80Exp: 2033-12-08→ Common Stock (276,000 underlying)
Footnotes (1)
- [F1]The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.